7 results
The first objective is to evaluate the superiority of CHF 5259 pMDI (glycopyrrolate bromide) (50 µg total daily dose) versus placebo in terms of FEV1 AUC0-12h normalised by time on Day 42.Key Secondary objectiveTo evaluate the superiority of CHF…
Primary objectives:* To assess telmisartan target (i.e. receptor) specific binding in vivo* To assess receptor occupancy of telmisartan in vivo* To determine optimal scanning time in vivoSecondary objective:* To explore the effect of telmisartan on…
Parts D and E: Primary Objectives:• To evaluate the safety and tolerability of VX-445 in TC with TEZ and IVA in subjects with cystic fibrosis (CF)• To evaluate the efficacy of VX-445 in TC with TEZ and IVA in subjects with CFSecondary Objectives• To…
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
In this study we would like to study the effects of the selective angiotensin II antagonist Telmisartan on inflammation and cell/matrix homeostasis in the human aneurysm aortic wall.
A better understanding on the individual response to different albuminuria lowering drugs and a better understanding why these drugs, of which some are developed for another indication, may help to tailor optimal therapy. Therefore in this study…
The aim of this study is to investigate if telmisartan reduces AAA growth